Medication Nonadherence and the Risks of Hospitalization, Emergency Department Visits, and Death Among Medicare Part D Enrollees With Diabetes

The clinical benefits of intensive diabetes control using hypoglycemic agents, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in managing diabetes and preventing diabetes-related complications have been well established in clinical trials and longitudinal studies. However, 3-10 adherence to treatment regimens with these medications among patients with diabetes remains

[1]  C. Cooke,et al.  Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization. , 2015, Journal of managed care pharmacy : JMCP.

[2]  Timothy W. Smith,et al.  Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[4]  J. Steiner,et al.  A Systematic Review of the Literature , 2019, HIV/AIDS and Adolescents.

[5]  Won Chan Lee,et al.  Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings , 2005, Journal of managed care pharmacy : JMCP.

[6]  Denys T. Lau,et al.  Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. , 2004, Diabetes care.

[7]  A. Unger,et al.  Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. , 2005, Clinical therapeutics.

[8]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[9]  James M Wright,et al.  Statin Adherence and Risk of Accidents: A Cautionary Tale , 2009, Circulation.

[10]  R. Rubin,et al.  Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. , 2005, The American journal of medicine.

[11]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[12]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[13]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[14]  C. Pashos,et al.  Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. , 2006, Managed care interface.

[15]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[16]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[17]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[18]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[19]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[20]  Kirsten Bibbins-Domingo,et al.  Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering , 2009, Annals of Internal Medicine.

[21]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[22]  Richard Kahn,et al.  The impact of prevention on reducing the burden of cardiovascular disease. , 2008, Circulation.

[23]  F. Camacho,et al.  Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. , 2003, Clinical therapeutics.

[24]  David L McClure,et al.  Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease , 2006, BMC cardiovascular disorders.

[25]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[26]  H. Rodbard,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[27]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  L Keoki Williams,et al.  Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. , 2004, Diabetes care.

[29]  Richard H. Chapman,et al.  Predictors of adherence with antihypertensive and lipid-lowering therapy. , 2005 .

[30]  I. Lerman.  Adherence to treatment: the key for avoiding long-term complications of diabetes. , 2005, Archives of medical research.